Works matching Genentech Inc.

Results: 4247

Estimating Hypothetically Negotiated Royalty Rates after Medlmmune, Inc. v. Genentech, Inc., et al.

Published in:

Journal of Legal Economics, 2008, v. 14, n. 3, p. 43

By:

Porter Jr., Stevan D.

Publication type:

Article

DETHRONING LEAR? INCENTIVES TO INNOVATE AFTER MEDIMMUNE.

Published in:

Berkeley Technology Law Journal, 2009, v. 24, n. 2, p. 971

By:

Dreyfuss, Rochelle Cooper;
Pope, Lawrence S.

Publication type:

Article

Cabilly patent finale.

Published in:

Nature Biotechnology, 2008, v. 26, n. 8, p. 846, doi. 10.1038/nbt0808-846b

By:

Waltz, Emily

Publication type:

Article

Recent Supreme Court decisions and licensing power.

Published in:

Nature Biotechnology, 2008, v. 26, n. 2, p. 183, doi. 10.1038/nbt0208-183

By:

Giordano-Coltart, Jennifer;
Calkins, Charles W

Publication type:

Article

BURDEN OF PROOF IN MEDTRONIC: THE FEDERAL CIRCUIT'S IDIOSYNCRATIC PATENT JURISPRUDENCE VETOED, AGAIN.

Published in:

Berkeley Technology Law Journal, 2015, v. 30, p. 777

By:

Zaharia, Sorin G.

Publication type:

Article

The Federal Circuit's Interpretation and Application of the MedImmune Standard for Declaratory Judgment Jurisdiction.

Published in:

Texas Intellectual Property Law Journal, 2011, v. 19, n. 3, p. 331

By:

Nix, Kelsey I.;
Stemplert, Laurie

Publication type:

Article

AN EXTRAORDINARY DECADE: THE SUPREME COURT TAKES CHARGE OF RESHAPING PATENT LAW.

Published in:

Charleston Law Review, 2010, v. 4, n. 4, p. 887

By:

Srisiri-Sisson, Warunee

Publication type:

Article

THE RETURN OF THE KING: RETHINKING LEAR, MEDIMMUNE, AND THE EFFECTS OF LICENSEE ESTOPPEL IN THE CONTEXT OF AIA POST-GRANT PROCEDURES.

Published in:

New York University Annual Survey of American Law, 2015, v. 71, n. 1, p. 81

By:

GREENE, SCOTT G.

Publication type:

Article

DECLARATORY RELIEF AFTER MEDIMMUNE.

Published in:

Lewis & Clark Law Review, 2010, v. 14, n. 2, p. 491

By:

Levine, David I.;
Belle, Charles E.

Publication type:

Article

US allows patent dilution.

Published in:

Chemistry & Industry, 2007, n. 2, p. 9

By:

Walker, Patrick

Publication type:

Article

Supreme Court Says You Can License and Sue.

Published in:

Research Technology Management, 2007, v. 50, n. 2, p. 9

By:

Berkowitz, Leonard

Publication type:

Article

U.S. Supreme Court Makes It Easier for Patent Licensee to Have Its Cake and Eat It Too.

Published in:

JOM: The Journal of The Minerals, Metals & Materials Society (TMS), 2007, v. 59, n. 4, p. 80, doi. 10.1007/s11837-007-0057-9

By:

Silverman, Arnold B.

Publication type:

Article

Supreme Court sides with MedImmune.

Published in:

Nature Reviews Drug Discovery, 2007, v. 6, n. 2, p. 104, doi. 10.1038/nrd2249

By:

Harrison, Charlotte;
Owens, Joanna

Publication type:

Article

EXPANDING STANDING IN PATENT DECLARATORY JUDGMENT ACTIONS TO BETTER AIR PUBLIC POLICY CONSIDERATIONS.

Published in:

New York University Law Review, 2013, v. 88, n. 1, p. 476

By:

WALRATH, NICHOLAS D.

Publication type:

Article

Medimmune v. Genentech: A Game-Theoretic Analysis of the Supreme Court's Continued Assault on the Patentee.

Published in:

Marquette Intellectual Property Law Review, 2011, v. 15, n. 2, p. 503

By:

SMITH, NICHOLAS G.

Publication type:

Article

Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphomaThe development of the model and the subsequent analyses were supported by a grant from Genentech, Inc. The sponsors of the study had no role in the model design, cost-utility analysis, or interpretation of the results. All investigators had unlimited access to the model and data. No limitations on publication were imposed. The authors made the final decisions on all analyses presented in the article.

Published in:

Cancer (0008543X), 2005, v. 103, n. 8, p. 1644

By:

John C. Hornberger;
Jennie H. Best

Publication type:

Article

Great company, bad stock.

Published in:

Nature Biotechnology, 2005, v. 23, n. 2, p. 173, doi. 10.1038/nbt0205-173

By:

Jacobs, Tom

Publication type:

Article

Genentech relaunched with independence intact.

Published in:

Nature Biotechnology, 1999, v. 17, n. 7, p. 634, doi. 10.1038/10842

By:

Glaser, Vicki

Publication type:

Article

Intravitreal Ranibizumab Tedavisi Uygulanan Retina Ven Dal Tıkanıklığına Bağlı Maküla Ödemi Olgularında Görme Keskinliğine Etki Eden Prognostik Faktörler.

Published in:

Retina-Vitreus/Journal of Retina-Vitreous, 2014, v. 22, n. 2, p. 103

By:

DEMİREL, Sibel;
ALAY, Cem;
BATIOĞLU, Figen;
ÖZMERT, Emin

Publication type:

Article

How Much Is More Life Worth?

Published in:

2006

By:

Brock, Dan W.

Publication type:

Editorial

Treat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON study.

Published in:

International Journal of Retina & Vitreous, 2019, v. 5, n. 1, p. N.PAG, doi. 10.1186/s40942-019-0159-x

By:

Khurana, Rahul N.;
Chang, Louis K.;
Bansal, Alok S.;
Palmer, James D.;
Wu, Chengqing;
Wieland, Mark R.

Publication type:

Article

Genentech raises stakes on PARP inhibitors.

Published in:

Nature Biotechnology, 2006, v. 24, n. 10, p. 1179, doi. 10.1038/nbt1006-1179

By:

Sheridan, Cormac

Publication type:

Article

A historical perspective on convergence technology.

Published in:

Nature Biotechnology, 2006, v. 24, n. 3, p. 280, doi. 10.1038/nbt0306-280

By:

Patton, John S.

Publication type:

Article

GlaxoSmithKline cancer drug threatens Herceptin market.

Published in:

Nature Biotechnology, 2005, v. 23, n. 12, p. 1453, doi. 10.1038/nbt1205-1453

By:

Waltz, Emily

Publication type:

Article

People.

Published in:: Nature Biotechnology, 2005, v. 23, n. 2, p. 249, doi. 10.1038/nbt0205-249
Publication type:: Article

The biotech drug market.

Published in:

Nature Biotechnology, 2004, v. 22, n. 12, p. 1496, doi. 10.1038/nbt1204-1496

By:

Lawrence, Stacy

Publication type:

Article

Genentech discloses safety concerns over Avastin.

Published in:

Nature Biotechnology, 2004, v. 22, n. 10, p. 1198, doi. 10.1038/nbt1004-1198

By:

Ratner, Mark

Publication type:

Article

CD18 trials disappoint again.

Published in:

Nature Biotechnology, 2000, v. 18, n. 8, p. 817, doi. 10.1038/78412

By:

Dove, Alan

Publication type:

Article

Genentech's 2nd IPO.

Published in:

Nature Biotechnology, 1999, v. 17, n. 9, p. 838, doi. 10.1038/12793

By:

Breithaupt, Holger

Publication type:

Article

Genentech enlightens other angiogenesis programs.

Published in:

Nature Biotechnology, 1999, v. 17, n. 4, p. 326, doi. 10.1038/7877

By:

Brower, Vicki

Publication type:

Article

ASCPT News.

Published in:: Clinical Pharmacology & Therapeutics, 2021, v. 110, n. 3, p. 535, doi. 10.1002/cpt.2365
Publication type:: Article

CITY OF HOPE V. GENENTECH: KEEPING FIDUCIARY DUTIES WHERE THEY BELONG.

Published in:

Berkeley Technology Law Journal, 2009, v. 24, n. 1, p. 179

By:

McBride, Reed C.

Publication type:

Article

DECLARATORY JUDGMENT ACTIONS IN PATENT CASES: THE FEDERAL CIRCUIT'S RESPONSE TO MEDIMMUNE V. GENENTECH.

Published in:

Berkeley Technology Law Journal, 2008, v. 23, n. 1, p. 161

By:

Saionz, Jennifer R.

Publication type:

Article

Roche bids for remaining Genentech stake.

Published in:: Nature, 2008, v. 454, n. 7203, p. 381, doi. 10.1038/454381a
Publication type:: Article

Business: Stepping out.

Published in:

Nature, 2008, v. 452, n. 7184, p. 146, doi. 10.1038/452146a

By:

Dalton, Rex

Publication type:

Article

No approval.

Published in:: Nature, 2007, v. 450, n. 7172, p. 935, doi. 10.1038/450935c
Publication type:: Article

In brief.

Published in:: Nature, 2006, v. 442, n. 7099, p. 123, doi. 10.1038/442123a
Publication type:: Article

In brief.

Published in:: Nature, 2006, v. 439, n. 7079, p. 911, doi. 10.1038/439911a
Publication type:: Article

In brief.

Published in:: Nature, 2006, v. 439, n. 7074, p. 265, doi. 10.1038/439265b
Publication type:: Article

Movers.

Published in:

Nature, 2004, v. 428, n. 6982, p. 586, doi. 10.1038/nj6982-586c

By:

Dixit, Vishva

Publication type:

Article

Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC.

Published in:

Oncologist, 2008, v. 13, n. 11, p. 1166, doi. 10.1634/theoncologist.2008-0108

By:

HERBST, ROY S.;
SANDLER, ALAN

Publication type:

Article

Current Developments in State and Local Tax.

Published in:

Journal of State Taxation, 2015, v. 33, n. 2, p. 7

By:

Bernard, Mary F.;
Nachbar, Mark L.

Publication type:

Article

New indication.

Published in:: 2009
Publication type:: Product Review

FDA actions in brief.

Published in:: Formulary, 2008, v. 43, n. 4, p. 121
Publication type:: Article

Tarceva.

Published in:: Formulary, 2005, v. 40, n. 12, p. 425
Publication type:: Article

A year of novel pharmacologic agents in review.

Published in:: Formulary, 2004, v. 39, n. 12, p. 572
Publication type:: Article

New molecular entities.

Published in:: Formulary, 2004, v. 39, n. 12, p. 568
Publication type:: Article

Study Aims to Clarify Efficacy, Safety of Eye Drug Treatments.

Published in:

JAMA: Journal of the American Medical Association, 2007, v. 297, n. 14, p. 1538, doi. 10.1001/jama.297.14.1538

By:

Mitka, Mike

Publication type:

Article

Phase III/IV.

Published in:: Applied Clinical Trials, 2005, v. 14, n. 7, p. 14
Publication type:: Article

Product News.

Published in:: Dermatology Nursing, 2007, v. 19, n. 2, p. 194
Publication type:: Article